1. Academic Validation
  2. Comparison of fluconazole and SDZ89-485 for therapy of experimental murine coccidioidomycosis

Comparison of fluconazole and SDZ89-485 for therapy of experimental murine coccidioidomycosis

  • Antimicrob Agents Chemother. 1990 Jan;34(1):13-6. doi: 10.1128/AAC.34.1.13.
J Fierer 1 T Kirkland F Finley
Affiliations

Affiliation

  • 1 Department of Medicine, Veterans Administration Medical Center, San Diego, California 92161.
Abstract

We infected mice with arthroconidia of Coccidioides immitis by intraperitoneal injection and 48 h later treated them with either oral fluconazole or SDZ89-485, a new triazole. Both drugs completely inhibited Fungal growth when administered at a dose of 50 mg/kg of body weight twice a day, but only SDZ89-485 was fully inhibitory at a dose of 5 mg/kg twice a day. In a second experiment, treatment with SDZ89-485 was delayed until 8 days after Infection to allow Infection to be well established before treatment. Both 5 and 50 mg/kg twice a day were effective regimens, which establishes that SDZ89-485 has activity against spherules in vivo. Mice that received fluconazole (50 mg/kg twice a day) had a peak level in blood of 60 micrograms/ml 1 h after a dose, but no measurable amount was found after 12 h. SDZ89-485 was more slowly absorbed, reaching a peak level in blood of 14 micrograms/ml at 12 to 15 h after a dose of 50 mg/kg. We conclude that SDZ89-485 is more effective than fluconazole as treatment for experimental systemic coccidioidomycosis in mice, even though fluconazole achieves higher peak levels in blood.

Figures
Products